Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-linolenic acid (ALA) is an essential omega-3 polyunsaturated fatty acid found in plant sources like flaxseed, walnuts, and chia seeds. In the context of neurodegenerative research, ALA serves as a metabolic precursor for the endogenous synthesis of long-chain omega-3 fatty acids, specifically docosahexaenoic acid (DHA). This metabolic pathway is particularly relevant for APOE4 carriers, who often exhibit impaired DHA transport across the blood-brain barrier (BBB) and reduced brain DHA levels. By providing ALA, researchers aim to bypass transport limitations and support cerebrovascular health, BBB integrity, and cognitive function in populations at high risk for Alzheimer's disease, such as those with mild cognitive impairment (MCI). ALA also acts as a signaling molecule, activating G protein-coupled receptors and peroxisome proliferator-activated receptors (PPARs) to exert anti-inflammatory and neuroprotective effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-linolenic acid (Icahn School of Medicine at Mount Sinai).